Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01079234 · ClinicalTrials.gov registry record · Phase 3
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 493
- Enrollment target
NCT01079234 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 493 participants.
The verdict
NCT01079234, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 493 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.
Interventions
- DRUG insulin aspart
- DRUG insulin glargine
- DRUG insulin degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 493 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01079234
The ClinicalTrials.gov registry entry for NCT01079234 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 493 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which insulin aspart is the first listed.
NCT01079234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01079234 about?
NCT01079234 is a clinical study titled "Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes". This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.
What is the current status of trial NCT01079234?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 493 participants. The study started on 2010-03. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01079234?
The interventions under investigation include: insulin aspart (DRUG), insulin glargine (DRUG), insulin degludec (DRUG).
Who is sponsoring clinical trial NCT01079234?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.